CC
PSTX

Callan Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Callan Capital’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-108,080
Closed -$309K – 374
2024
Q3 		$309K Buy
108,080
+24,000
+29% +$74.3K 0.02% 256
2024
Q2 		$246K Buy
84,080
+5,500
+7% +$15K 0.02% 262
2024
Q1 		$251K Buy
78,580
+2,021
+3% +$6.74K 0.02% 237
2023
Q4 		$257K Hold
76,559
– – 0.02% 188
2023
Q3 		$182K Buy
76,559
+4,000
+6% +$8.38K 0.02% 192
2023
Q2 		$128K Buy
72,559
+4,552
+7% +$11.6K 0.01% 176
2023
Q1 		$209K Buy
68,007
+5,660
+9% +$33.9K 0.02% 170
2022
Q4 		$330K Buy
+62,347
New +$285K 0.04% 133

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Callan Capital's PSTX Position: Q4 2024 in Review

Callan Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 108,080 shares — an estimated $309K sold.

Callan Capital first reported a position in PSTX in Q4 2022 and held it in 8 quarters. The position peaked at $330K in Q4 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Callan Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Callan Capital sold 108,080 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $309K.
  • Callan Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 8 quarters.
  • Callan Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $330K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Callan Capital's 13F filing for Q4 2024, filed 3 Feb 2025.